Research and Evaluation Initiative Office on Violence Against Women/Department of Justice

L-&-D_logo.30 OVW-2018-14240 06-Feb-2018 [Optional] 2,400,000.00 USD
Contact Email virginia.baran@usdoj.gov
Sponsor Website https://www.grants.gov/web/grants/view-opportunity.html?oppId=300012
Program URL https://www.justice.gov/ovw/file/1025226/download
Deadline Dates (ALL) 06-Feb-2018 [Optional], 05-Mar-2018
Synopsis  

The purpose of the Research and Evaluation (R&E) initiative is to research and evaluate approaches to combating domestic violence, sexual assault, dating violence, and stalking. By generating more knowledge about strategies for serving victims and holding offenders accountable, communities that benefit from VAWA funding will be better equipped to align their work with practices that are known to be effective, and they will be more capable of generating empirical knowledge on the efficacy of new and promising ways of doing things.

Advertisements
| Leave a comment

Academic Enrichment Grants McCarthey Dressman Education Foundation

L-&-D_logo.30 15-Apr-2018 30,000.00 USD
Contact Telephone 801-578-1260
Contact Email info@mccartheydressman.org
Sponsor Website http://mccartheydressman.org/
Program URL http://mccartheydressman.org/academic-enrichment-grants/
Deadline Dates (ALL) 15-Apr-2018
Synopsis The McCarthey Dressman Education Foundation offers Academic Enrichment Grants designed to develop in-class and extra-curricular programs that improve student learning. The Foundation considers proposals that foster understanding, deepen students’ knowledge, and provide opportunities to expand awareness of the world around them.
| Leave a comment

NIH Program Announcements

L-&-D_logo.30

  • Hearing Health Care for Adults: Improving Access and Affordability (R21 Clinical Trial Optional)
    (PA-18-382)
    National Institute on Deafness and Other Communication Disorders
    Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  • Hearing Health Care for Adults: Improving Access and Affordability (R01 Clinical Trial Optional)
    (PA-18-438)
    National Institute on Deafness and Other Communication Disorders
    Application Receipt/Submission Date(s): Standard dates apply , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  • Complex Technologies and Therapeutics Development for Mental Health Research and Practice (R43/R44 Clinical Trial Optional)
    (PA-18-566)
    National Institute of Mental Health
    Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization.
  • Competing Renewal Awards of SBIR Phase IIB Grants for Brain and Behavior Tools (R44 Clinical Trial Optional)
    (PA-18-567)
    National Institute of Mental Health
    Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. *** Note new SBIR/STTR Standard Due Dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • International Research Collaboration on Drug Abuse and Addiction Research (R01, Clinical Trial Optional)
    (PA-18-568)
    National Institute on Drug Abuse
    Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  • Underactive Bladder and Detrusor Activity in Aging (R01 Clinical Trial Optional)
    (PA-18-570)
    National Institute on Aging
    National Institute of Diabetes and Digestive and Kidney Diseases
    Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  • Underactive Bladder and Detrusor Activity in Aging (R03 Clinical Trial Optional)
    (PA-18-571)
    National Institute on Aging
    Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  • Underactive Bladder and Detrusor Activity in Aging (R21 Clinical Trial Optional)
    (PA-18-572)
    National Institute on Aging
    Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  • Complex Technologies and Therapeutics Development for Mental Health Research and Practice (R41/R42)
    (PA-18-579)
    National Institute of Mental Health
    Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization.
  • NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Clinical Trial Required)
    (PAR-18-435)
    National Institute on Deafness and Other Communication Disorders
    Application Receipt/Submission Date(s): February 15, 2018; June 19, 2018; October 19, 2018; February 15, 2019; June 18, 2019; October 17, 2019; February 13, 2020; June 18, 2020; and October 15, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 – No Independent Clinical Trials)
    (PAR-18-436)
    National Institute on Deafness and Other Communication Disorders
    Application Receipt/Submission Date(s): February 15, 2018; June 19, 2018; October 19, 2018; February 15, 2019; June 18, 2019; October 17, 2019; February 13, 2020; June 18, 2020; and October 15, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  • Cutting-Edge Basic Research Awards (CEBRA) (R21-Clinical Trial Optional)
    (PAR-18-437)
    National Institute on Drug Abuse
    Application Receipt/Submission Date(s): August 20, 2018; December 20, 2018; August 20, 2019; December 20, 2019; August 20, 2020; and December 18, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  • NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (U01 – Clinical Trial Optional)
    (PAR-18-561)
    National Institute of Neurological Disorders and Stroke
    Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • NIDCD Research Career Enhancement Award for Established Investigators (K18 -Clinical Trials Required)
    (PAR-18-562)
    National Institute on Deafness and Other Communication Disorders
    Application Receipt/Submission Date(s): February 8, 2018; June 8, 2018; October 9, 2018; February 8, 2019; June 6, 2019; October 8, 2019; February 6, 2020; June 8, 2020; and October 8, 2020 , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  • NIH StrokeNet Small Business Innovation Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (U44 – Clinical Trials Optional)
    (PAR-18-563)
    National Institute of Neurological Disorders and Stroke
    Application Receipt/Submission Date(s): Standard dates apply , by 5:00 PM local time of applicant organization.
  • NIDCD Research Career Enhancement Award for Established Investigators (K18 – No Independent Clinical Trials)
    (PAR-18-564)
    National Institute on Deafness and Other Communication Disorders
    Application Receipt/Submission Date(s): February 8, 2018; June 8, 2018; October 9, 2018; February 8, 2019; June 6, 2019; October 8, 2019; February 6, 2020; June 8, 2020; and October 8, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  • Lab to Marketplace: Tools for Brain and Behavioral Research (R43/R44 – Clinical Trial Optional
    (PAR-18-565)
    National Institute of Mental Health
    Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization.
  • New Epidemiology Cohort Studies in Heart, Lung, Blood, and Sleep Diseases and Disorders (U01 – Clinical Trials Not Allowed)
    (PAR-18-577)
    National Heart, Lung, and Blood Institute
    Application Receipt/Submission Date(s): June 5, 2018, June 5, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  • Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use disorder and Alcohol-related disorders (U44 – Clinical Trial Optional)
    (PAR-18-578)
    National Institute on Alcohol Abuse and Alcoholism
    Application Receipt/Submission Date(s): March 27, 2018; December 4, 2018; March 27, 2019; December 4, 2019; March 27, 2020; December 4, 2020, by 5:00 PM local time of applicant organization.
  • Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use disorder and Alcohol-related disorders (UT2 -Clinical Trial Optional)
    (PAR-18-580)
    National Institute on Alcohol Abuse and Alcoholism
    Application Receipt/Submission Date(s): March 27, 2018; December 4, 2018; March 27, 2019; December 4, 2019; March 27, 2020; December 4, 2020, by 5:00 PM local time of applicant organization.
  • Emotional Function in Normal Aging and/or MCI and AD/ADRD (R01 – Clinical Trial Optional)
    (PAR-18-581)
    National Institute on Aging
    Application Receipt/Submission Date(s): March 29, 2018; June 8, 2018; February 8, 2019; June 7, 2019; February 7, 2020; and June 8, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  • Emotional Function in Normal Aging and/or MCI and AD/ADRD (R21 – Clinical Trial Not Allowed)
    (PAR-18-582)
    National Institute on Aging
    Application Receipt/Submission Date(s): March 29, 2018; June 20, 2018; February 20, 2019; June 20, 2019; February 20, 2020; and June 22, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
| Leave a comment

NIH Requests for Applications

L-&-D_logo.30

  • Pediatric Device Consortia Grants Program (P50)
    (RFA-FD-18-004)
    Food and Drug Administration
    Application Receipt Date(s): March 1, 2018, by 11:59 PM Eastern Time. December 1, 2018, by 11:59 PM Eastern Time. December 1, 2019, by 11:59 PM Eastern Time. December 1, 2020, by 11:59 PM Eastern Time. December 1, 2021, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
  • Patient Safety Learning Laboratories: Pursuing Safety in Diagnosis and Treatment at the Intersection of Design, Systems Engineering, and Health Services Research (R18)
    (RFA-HS-18-001)
    Agency for Healthcare Research and Quality
    Application Receipt Date(s): March 26, 2018, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date
  • African Association for Health Professions Education and Research (R25)(Clinical Trials Not Allowed)
    (RFA-TW-18-001)
    John E. Fogarty International Center
    Application Receipt Date(s): March 28, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
| Leave a comment

Damon Runyon Fellowship Award Damon Runyon Cancer Research Foundation

L-&-D_logo.30 15-Mar-2018 0.00 USD
Sponsor Website https://www.damonrunyon.org/for-scientists/award-programs
Program URL https://www.damonrunyon.org/for-scientists/application-guidelines/fellowship
Deadline Dates (ALL) 15-Mar-2018, 15-Aug-2018
Synopsis The Damon Runyon Fellowship Award supports the training of the brightest postdoctoral scientists as they embark upon their research careers. This funding enables them to be trained by established investigators in leading research laboratories across the country.
| Leave a comment

NIH Notices

L-&-D_logo.30

  • NIH Operates Under a Continuing Resolution Through January 19, 2018
    (NOT-OD-18-124) National Institutes of Health
  • Reminder: Updated Appendix Policy Eliminates Clinical Trial-Related Materials for NIH/AHRQ/NIOSH Applications Submitted to Due Dates on or After January 25, 2018
    (NOT-OD-18-126) National Institutes of Health
  • Notice of Expiration of PAR-16-269 “NIAID Clinical Trial Implementation Grant (R01)”
    (NOT-AI-18-009)
    National Institute of Allergy and Infectious Diseases
  • Notice of Clarification to RFA-AI-17-042, Centers of Excellence for Translational Research (CETR) (U19 Clinical Trial Not Allowed)
    (NOT-AI-18-011)
    National Institute of Allergy and Infectious Diseases
  • Notice of Expiration of PAR-16-447 ” NIAMS Clinical Trial Implementation Cooperative Agreement (U01)
    (NOT-AR-18-014)
    National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • Notice of Intent to Publish a Funding Opportunity Announcement for Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R01, Clinical Trial Optional)
    (NOT-DA-17-058)
    National Institute on Drug Abuse
    National Institute on Alcohol Abuse and Alcoholism
  • Notice of Plans to Allow 13 NIDA Program Announcements to Expire Without Renewal and Guidance to Applicants on how to Apply for Research Grants in Those Topic Areas
    (NOT-DA-17-065)
    National Institute on Drug Abuse
  • Notice of NIDCD Withdrawal from Participation in PAR-18-215 “Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R01 Clinical Trial Optional)”
    (NOT-DC-18-003)
    National Institute on Deafness and Other Communication Disorders
  • Notice of NIDCD Withdrawal from Participation in PAR-18-214 “Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R21 Clinical Trial Optional)”
    (NOT-DC-18-004)
    National Institute on Deafness and Other Communication Disorders
  • Notice of Correction to the Number of Applications per Institution Allowed for RFA DE-18-012, “NIDCR Dental Specialty and PhD Program (DSPP) (K12) Clinical Trial Not Allowed)”.
    (NOT-DE-18-005)
    National Institute of Dental and Craniofacial Research
  • NIDCR Announces a Pre-Application Webinar and the Availability of Answers to Questions for RFA DE-18-012 “NIDCR Dental Specialty and PhD Program (DSPP) (K12 Clinical Trial Not Allowed)”
    (NOT-DE-18-006)
    National Institute of Dental and Craniofacial Research
  • Notice of NIDCR’s Participation in PAR-18-009 “Academic-Industrial Partnerships to Translate and Validate in vivo Cancer Imaging Systems (R01 Clinical Trial Optional)”
    (NOT-DE-18-007)
    National Institute of Dental and Craniofacial Research
  • Notice of NIDCR’s Participation in PAR-18-530 ” Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 – Clinical Trial Optional)”
    (NOT-DE-18-008)
    National Institute of Dental and Craniofacial Research
  • Notice of Clarification of Studies Appropriate for PAR-18-112: Diet and Physical Activity Assessment Methodology (R21 Clinical Trial Optional)
    (NOT-DK-18-003)
    National Institute of Diabetes and Digestive and Kidney Diseases
    National Cancer Institute
    National Heart, Lung, and Blood Institute
    National Institute on Alcohol Abuse and Alcoholism
    Eunice Kennedy Shriver National Institute of Child Health and Human Development
    National Institute of Nursing Research
    Office of Dietary Supplements
  • Notice of Clarification of Studies Appropriate for PA-18-010: Diet and Physical Activity Assessment Methodology (R01 Clinical Trial Optional)
    (NOT-DK-18-004)
    National Institute of Diabetes and Digestive and Kidney Diseases
    National Center for Complementary and Integrative Health
    National Cancer Institute
    National Heart, Lung, and Blood Institute
    National Institute on Alcohol Abuse and Alcoholism
    Office of Dietary Supplements
  • Clarification on the Number of Applications Allowed Per Organization for RFA-DK-17-017: Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01 Clinical Trial Optional)
    (NOT-DK-18-007)
    National Institute of Diabetes and Digestive and Kidney Diseases
  • Clarification on the Number of Applications Allowed Per Organization for RFA-DK-17-018: Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R21 Clinical Trial Optional)
    (NOT-DK-18-008)
    National Institute of Diabetes and Digestive and Kidney Diseases
  • NIBIB Notice of Clarification of Preliminary Data and Clinical Trials Support for PAR-18-207, NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)
    (NOT-EB-18-003)
    National Institute of Biomedical Imaging and Bioengineering
  • Notice of Key Date Changes for RFA-EY-17-003 “NEI Audacious Goals Initiative: Translation-Enabling Models to Evaluate Survival and Integration of Regenerated Neurons in the Visual System (U24 Clinical Trials Not Allowed)”
    (NOT-EY-18-005)
    National Eye Institute
  • Notice of Clarification of Applications Relevant to PAR-17-046 “Exploratory Research for Technology Development (R21)”
    (NOT-GM-18-014)
    National Institute of General Medical Sciences
  • NHLBI Announces Plan to Fund a Framingham Heart Study Exam
    (NOT-HL-17-572)
    National Heart, Lung, and Blood Institute
  • Notice of Intent to Publish a Funding Opportunity Announcement to Support New Applications in Regenerative Medicine Innovation Projects (RMIP) (UG3/UH3 – Clinical Trial Required)
    (NOT-HL-18-573)
    National Heart, Lung, and Blood Institute
    Food and Drug Administration
    National Center for Advancing Translational Sciences
    National Eye Institute
    National Institute on Aging
    National Institute of Allergy and Infectious Diseases
    National Institute of Arthritis and Musculoskeletal and Skin Diseases
    National Institute of Biomedical Imaging and Bioengineering
    National Institute on Deafness and Other Communication Disorders
    National Institute of Dental and Craniofacial Research
    National Institute of Diabetes and Digestive and Kidney Diseases
    National Institute of Mental Health
    National Institute of Neurological Disorders and Stroke
  • Notice of Intent to Publish a Funding Opportunity Announcement to Support New Applications in Regenerative Medicine Innovation Projects (RMIP) (U01 – Clinical Trial Not Allowed)
    (NOT-HL-18-574)
    National Heart, Lung, and Blood Institute
    Food and Drug Administration
    National Center for Advancing Translational Sciences
    National Eye Institute
    National Institute on Aging
    National Institute of Allergy and Infectious Diseases
    National Institute of Arthritis and Musculoskeletal and Skin Diseases
    National Institute of Biomedical Imaging and Bioengineering
    National Institute on Deafness and Other Communication Disorders
    National Institute of Dental and Craniofacial Research
    National Institute of Diabetes and Digestive and Kidney Diseases
    National Institute of Mental Health
    National Institute of Neurological Disorders and Stroke
  • Notice of Intent to Publish a Funding Opportunity Announcement to Support New Applications in Regenerative Medicine Innovation Projects (RMIP) (UT1/UT2 – Clinical Trial Required)
    (NOT-HL-18-575)
    National Heart, Lung, and Blood Institute
    Food and Drug Administration
    National Center for Advancing Translational Sciences
    National Eye Institute
    National Institute on Aging
    National Institute of Allergy and Infectious Diseases
    National Institute of Biomedical Imaging and Bioengineering
    National Institute on Deafness and Other Communication Disorders
    National Institute of Dental and Craniofacial Research
    National Institute of Diabetes and Digestive and Kidney Diseases
    National Institute of Mental Health
    National Institute of Neurological Disorders and Stroke
  • Notice of Intent to Publish a Funding Opportunity Announcement to Support New Applications in Regenerative Medicine Innovation Projects (RMIP) (UT1/UT2 – Clinical Trial Not Allowed)
    (NOT-HL-18-576)
    National Heart, Lung, and Blood Institute
    Food and Drug Administration
    National Center for Advancing Translational Sciences
    National Eye Institute
    National Institute on Aging
    National Institute of Allergy and Infectious Diseases
    National Institute of Arthritis and Musculoskeletal and Skin Diseases
    National Institute of Biomedical Imaging and Bioengineering
    National Institute on Deafness and Other Communication Disorders
    National Institute of Dental and Craniofacial Research
    National Institute of Diabetes and Digestive and Kidney Diseases
    National Institute of Mental Health
    National Institute of Neurological Disorders and Stroke
  • Notice of Intent to Publish a Funding Opportunity Announcement to Support New Applications in Regenerative Medicine Innovation Projects (RMIP) (U43/U44 – Clinical Trial Required)
    (NOT-HL-18-577)
    National Heart, Lung, and Blood Institute
    Food and Drug Administration
    National Center for Advancing Translational Sciences
    National Eye Institute
    National Heart, Lung, and Blood Institute
    National Institute on Aging
    National Institute of Allergy and Infectious Diseases
    National Institute of Biomedical Imaging and Bioengineering
    National Institute on Deafness and Other Communication Disorders
    National Institute of Dental and Craniofacial Research
    National Institute of Diabetes and Digestive and Kidney Diseases
    National Institute of Mental Health
    National Institute of Neurological Disorders and Stroke
  • Notice of Intent to Publish a Funding Opportunity Announcement to Support New Applications in Regenerative Medicine Innovation Projects (RMIP) (U43/U44 – Clinical Trial Not Allowed)
    (NOT-HL-18-578)
    National Heart, Lung, and Blood Institute
    Food and Drug Administration
    National Center for Advancing Translational Sciences
    National Eye Institute
    National Institute on Aging
    National Institute of Allergy and Infectious Diseases
    National Institute of Arthritis and Musculoskeletal and Skin Diseases
    National Institute of Biomedical Imaging and Bioengineering
    National Institute on Deafness and Other Communication Disorders
    National Institute of Dental and Craniofacial Research
    National Institute of Diabetes and Digestive and Kidney Diseases
    National Institute of Mental Health
    National Institute of Neurological Disorders and Stroke
  • Correction to the Application Forms Package issued for PAR-18-410 Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
    (NOT-HL-18-579)
    National Heart, Lung, and Blood Institute
  • Correction to the Application Forms Package issued for PAR-18-18-407 Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
    (NOT-HL-18-580)
    National Heart, Lung, and Blood Institute
  • Notice of Corrected Expiration Date for PA-15-354 “SBIR Technology Transfer (R43/R44)”
    (NOT-NS-18-031)
    National Institute of Neurological Disorders and Stroke
    National Center for Advancing Translational Sciences
    National Cancer Institute
    National Eye Institute
    National Institute on Alcohol Abuse and Alcoholism
    National Institute on Drug Abuse
    National Institute of Dental and Craniofacial Research
    National Institute of Nursing Research
  • Notice of Corrected Expiration Date and Intent to Reissue PAR-15-277 “NINDS Exploratory Clinical Trials for Small Business (R44)”
    (NOT-NS-18-032)
    National Institute of Neurological Disorders and Stroke
  • Notice of Corrected Expiration Date and Intent to Reissue PAR-15-278 “NINDS Exploratory Clinical Trials for Small Business (R42)”
    (NOT-NS-18-033)
    National Institute of Neurological Disorders and Stroke
  • Notice of Expiration of PAR-17-145 “NINDS Postdoctoral Mentored Career Development Award (K01)”
    (NOT-NS-18-034)
    National Institute of Neurological Disorders and Stroke
  • Notice of Expiration of PAR-16-340 “Career Transition Award for NINDS Intramural Clinician-Scientists (K22)”
    (NOT-NS-18-035)
    National Institute of Neurological Disorders and Stroke
  • Notice of Expiration of PAR-17-277 “NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention Infrastructure Resource Access (X01)”
    (NOT-NS-18-036)
    National Institute of Neurological Disorders and Stroke
  • Notice of Expiration of PAR-15-195 “NeuroNEXT Infrastructure Resource Access (X01)”
    (NOT-NS-18-037)
    National Institute of Neurological Disorders and Stroke
| Leave a comment

National Giving Program Walmart Foundation

L-&-D_logo.30 250,000.00 USD
Contact Telephone 479-273-4000
Sponsor Website http://giving.walmart.com/apply-for-grants/national-giving
Program URL http://giving.walmart.com/national-giving-guidelines
Synopsis The underlying focus is on empowering low-income people to help them live better. The National Giving Program allows the Foundation to work strategically with organizations working across one or more states to address social issues strongly aligned with the focus areas.
| Leave a comment